biotech · Relapsed/Refractory Large B Cell Lymphoma · Relapsed/Refractory Multiple Myeloma · ALLO
Allogene Therapeutics
Allogene Therapeutics is a biotech organization headquartered in South San Francisco, USA. It trades on NYSE under ticker ALLO. Primary therapeutic focus areas include Relapsed/Refractory Large B Cell Lymphoma, Relapsed/
South San Francisco, USA HQ
2017 Founded
208 Employees
Public company Type
ALLO · NYSE Ticker
Company details
- Status
- Public
- HQ
- South San Francisco, USA
- Founded
- 2017
- Employees
- 208
- Programs
- 8
- Drugs
- 2
- Patents
- 16
ALLO-501
Phase 1 · gene therapy · Relapsed/Refractory Large B Cell Lymphoma
ALLO-501 for Relapsed/Refractory Large B Cell Lymphoma is a Phase 1 program (gene_therapy) at Allogene Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code ALLO-501-201
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Allogene Therapeutics
- Phase
- Phase 1
- Modality
- gene_therapy
- Indication
- Relapsed/Refractory Large B Cell Lymphoma
- Status
- completed
- Trials
- 1